• A 12 month, phase 3, randomized, double-masked, multicenter, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia [Clinical Trial: CRFB001F2301]
  • A phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration [Clinical Trial: OPH1001A]
  • A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” Treatment algorithms vs. 0.5 mg ranibizumab as needed in patients with macular edema and visual Impairment secondary to Diabetes mellitus [Clinical Trial: CRFB002D2304] 
  • Visual outcomes after bilateral surgical cataract phacoemulsification: Acrysof® restor IOL implantation compared to monofocal IOL implantation [Clinical Trial: Alcon RDG-10-269]
  • A multicenter, randomized, double-masked, 2 parallel arm, vehicle controlled, 6-month phase 3 trial with a 6 month open label treatment safety follow-up period to evaluate the efficacy and safety of Cyclokat® 1mg/ml (ciclosporin/cyclosporine) eye drops, emulsion administered once daily in adult patients with severe dry eye disease (DED) [Clinical Trial: NVG10E117]
  • An open-label, multi-center, phase IIIb, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist [Clinical Trial: CRFB002DIT01]
  • Valutazione del profilo di tollerabilità e di efficacia di una soluzione oftalmica di acido glicirretico 5% e copolimero PEG/PPG (Saflogin®) in soggetti sani volontari e in soggetti affetti da blefarite [Clinical Trial: Med/OCU/2011/1]
  • A 2-year, multi center, phase IV, double-masked, randomized, parallel study of the safety of Lumigan® 0.1mg/ml compared with Lumigan® 0.3mg/ml in patients with glaucoma or ocular hypertension) [Clinical Trial: 192024-054]
  • A phase III, multinational, multicenter, randomized, double-masked, study assessing the safety and the efficacy of intravitreal injection of DE-109 (three doses) for the treatment of active, non infectious uveitis of the posterior segment of the eye [Clinical Trial: 32-007]
  • Phase II, 6-month double masked, multicenter, randomized, placebo-controlled, parallel group study to assess the safety and efficacy of topical administration of two concentrations of FOV2304 (1% and 2%) twice daily for the treatment of center-involving clinically significant macular edema associated with diabetic-retinopathy [Clinical Trial: FOV2304]
  • Single and repeat dose study (phase II) of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration [Clinical Trial: AGN-150998]
  • A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of individualized, stabilization criteria-driven pro re rata (PRN) dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy to patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) [Clinical Trial: CRFB002E2401]
  • A 24-month, phase IIIb, randomized, active-controlled, three-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria driven PRN dosing regimen with 0.5 mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) [Clinical Trial: CRFB002E2402]
  • Efficacy and safety assessment of intracameral T2830 (fixed combination of lidocaine, phenylephrine and tropicamide) for mydrisias and anaesthesia in phacoemulsification cataract surgery; phase III study, multicentre, international, randomized, open, versus reference group (topical mydriatics and anaesthetic) [Clinical Trial: LT2380]
  • Multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of 0.010% cyclosporine ophthalmic solution compared to its vehicle, administered four times a day (QID) for three months, followed by a 9-Month open phase, on patients with atopic keratoconjunctivitis [Clinical Trial: 192371-016]
  • A phase II study comparing Brivudin® 0.1% ophthalmic solution with Aciclovir 3.0% ophthalmic ointment in the treatment of patients with herpetic dendritic keratitis [Clinical Trial: 2-BOPH]
  • An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have completed the RESTORE trial [Clinical Trial: CRFB002D2301E1]
  • Efficacy and tolerance of a new hydrophobic acrylic aspheric intraocular lens [Clinical Trial: LR 301-08]
  • A multicenter, masked, randomized, sham-controlled, paired-eye comparison, 12-Month (plus 12-Month extension) study to evaluate the safety and effects on retinal structure and visual function of brimonidine tartrate posterior segment drug delivery system (Brimonidine® Tartrate PS DDS) applicator system in patients with geographic atrophy from Age-related macular degeneration [Clinical Trial: 190342-032D-03]
  • A 3-Year, phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700μg and 350μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema [Clinical Trial: AGN 206207-011]
  • Evaluation of the therapeutic equivalence of Travoprost® PR and Travatan®. Double blind randomized clinical trial in subjects affected by glaucoma or intraocular hypertension [Clinical Trial: Travoprost 01/2011]
  • A multicenter, patient-masked, safety extension study to evaluate the biodegradation of the Brimonidine Tartrate Segment Drug Delivery System [Clinical Trial: 190342-033D]
  • A multicenter, double-masked, randomized study to compare the safety and efficacy of an investigational eye drop formulation with Optive® unit-dose for 3-Months in subjects with dry eye disease [Clinical Trial: 11002X-001]
  • A multicenter, open-label, randomized study comparing the efficacy and safety of 700μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in patients with diabetic macular edema [Clinical Trial: 206207-024]
  • An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluate the safety and efficacy of two doses (10μg/ml or 20μg/ml) of recombinant human nerve growth factor eye drops solution versus vehicle in patients with stage 2 and 3 of neurotrophic keratitis [Clinical Trial: NGF0212]

mail fb twitter

Powered by YOUR NET SOLUTION - Tutti i diritti riservati